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1. INTRODUCTION {#cas13871-sec-0001}
===============

Malignant pleural mesothelioma, an aggressive neoplasm that arises from pleural mesothelial cells, is associated with asbestos exposure after 20‐40 years of latency.[1](#cas13871-bib-0001){ref-type="ref"}, [2](#cas13871-bib-0002){ref-type="ref"} Patients with MPM are usually diagnosed at an advanced stage of the disease, and their prognosis remains poor. Median survival after diagnosis is 6‐12 months, and the standard‐of‐care agents, pemetrexed and cisplatin, are relatively ineffective at increasing the survival time.[3](#cas13871-bib-0003){ref-type="ref"}, [4](#cas13871-bib-0004){ref-type="ref"} Asbestos could have multiple effects in carcinogenesis, but the molecular mechanisms underlying asbestos‐induced tumorigenesis are still unclear.[5](#cas13871-bib-0005){ref-type="ref"}, [6](#cas13871-bib-0006){ref-type="ref"}

Recent molecular biological studies have revealed frequent genetic alterations in patients with MPM, with 3 key tumor suppressor genes, *NF2*,*CDKN2A*, and *BAP1*, being identified at rates of 30%‐50%, 70%, and 20%‐60% in MPM cases, respectively.[7](#cas13871-bib-0007){ref-type="ref"}, [8](#cas13871-bib-0008){ref-type="ref"}, [9](#cas13871-bib-0009){ref-type="ref"}, [10](#cas13871-bib-0010){ref-type="ref"}, [11](#cas13871-bib-0011){ref-type="ref"}, [12](#cas13871-bib-0012){ref-type="ref"}, [13](#cas13871-bib-0013){ref-type="ref"} Moreover, the status of these 3 genes has significant prognostic implications. Homozygous *CDKN2A* deletions are a poor prognostic indicator for patients with MPM.[14](#cas13871-bib-0014){ref-type="ref"}, [15](#cas13871-bib-0015){ref-type="ref"}, [16](#cas13871-bib-0016){ref-type="ref"} Deletion of *NF2* is associated with increased cell proliferation, invasiveness, spreading, and migration.[17](#cas13871-bib-0017){ref-type="ref"}, [18](#cas13871-bib-0018){ref-type="ref"} However, the molecular mechanism by which normal mesothelial cells acquire a carcinogenic phenotype in humans is not well understood. In this study, we first examined the effect of *NF2* loss on the gene expression profile in human normal mesothelium cell line MeT‐5A and then characterized the cellular phenotype in vitro. We focused on one of the *NF2*‐related genes, *FGFR2*, and showed the involvement of *FGFR2* in the cellular phenotype in NF2‐KO cell clones. We also investigated the association between NF2 loss and FGFR2 expression in MPM tissues.

2. MATERIALS AND METHODS {#cas13871-sec-0002}
========================

2.1. Cell culture {#cas13871-sec-0003}
-----------------

Three immortalized normal human mesothelial cell lines, MeT‐5A (pleural mesothelial), HOMC‐A4 (omental mesothelial; sarcomatoid type), and HOMC‐D4 (omental mesothelial; intermediate type), and 1 human mesothelioma cell line, NCI‐H2052, were kindly provided by Dr. Y. Sekido, Division of Molecular Oncology, Aichi Cancer Center Research Institute (Nagoya, Japan). HOMC‐A4 and HOMC‐D4 cell lines were maintained as described elsewhere.[19](#cas13871-bib-0019){ref-type="ref"} MeT‐5A and NCI‐H2052 cell lines were maintained in RPMI‐1640 (Wako, Osaka, Japan) medium containing 10% FBS (Sigma‐Aldrich St. Louis, MO, USA) and penicillin‐streptomycin (Wako) at 37°C in a 5% CO~2~ air atmosphere.

2.2. Gene knockout using the CRISPR/Cas9 system {#cas13871-sec-0004}
-----------------------------------------------

The CRISPR/Cas9 system was used to disrupt the expression of the *NF2* and *FGFR2* genes, as described elsewhere.[20](#cas13871-bib-0020){ref-type="ref"} pSpCas9(BB)‐2A‐GFP (PX458) was a gift from Feng Zhang (plasmid \#48138; Addgene, Watertown, MA, USA ).[20](#cas13871-bib-0020){ref-type="ref"} In brief, an sgRNA sequence was selected using an Optimized CRISPR Design (<http://crispr.mit.edu/>). The sgRNA sequence for *NF2* was 5′‐AAACATCTCGTACAGTGACA‐3′ and that for *FGFR2* was 5′‐GTACCGTAACCATGGTCAGC‐3′, corresponding to exons 8 and 1, respectively. The plasmid expressing hCas9 and the sgRNA was prepared by ligating oligonucleotides into the *Bbs*I site of PX458 (NF2/PX458 and FGFR2/PX458). To establish a knockout clone, 1 μg NF2/PX458 or FGFR2/PX458 plasmid was nucleofected into cells (1 × 10^6^ cells) using a 4D‐Nucleofector instrument (Lonza Japan, Tokyo, Japan). After 3 days, the cells expressing GFP were sorted using FACS (BD Biosciences, San Jose, CA, USA). A single clone was selected, expanded, and then used for biological assays. For sequence analysis of the *NF2* gene, the following primer set was used: forward, 5′‐CAGTTTTGCTTCTACCTGCC‐3′ and reverse, 5′‐GCCAGTTGAGCTTCCCAGTT‐3′.

2.3. Construction of RNAi vectors and expression vectors {#cas13871-sec-0005}
--------------------------------------------------------

To construct an RNAi vector, sh oligonucleotide was inserted into pLentiLox3.7 plasmid (Addgene) under the control of the U6 promoter. Two sh oligonucleotides were designed for the target sequence of the hairpin loop of *YAP* (sh1, 5′‐TTCTATGTTCATTCCATCTCC‐3′; sh2, 5′‐GAGTTCTGACATCCTTAAT‐3′). A control shRNA vector was also constructed using a scrambled sequence for *YAP* (scr1, 5′‐GGATAAACTAAGGGATAGGAA‐3′). To construct the expression vector, cDNA fragments of WT *YAP* and *NF2* were amplified by PCR using Prime STAR Max DNA polymerase (Takara Bio, Otsu, Japan). The phosphorylation‐defective mutant YAP (YAP^S127/381A^) was constructed by in vitro mutagenesis at codons 127 and 381 from serine to alanine (S127/381A). The cDNA fragments were then introduced into the pcDNA3.1 expression vector (Addgene). Backbone pcDNA3.1 was used as a control vector. The cells (1 × 10^6^ cells) were nucleofected with 1 μg of each vector using a 4D‐Nucleofector instrument (Lonza Japan).

2.4. Quantitative real‐time PCR {#cas13871-sec-0006}
-------------------------------

Quantitative real‐time PCR analysis was carried out using SYBR Green I, as previously described.[21](#cas13871-bib-0021){ref-type="ref"} *GAPDH* was used as an internal control. The primers used in this study are described in [Table S1](#cas13871-sup-0005){ref-type="supplementary-material"}.

2.5. Complementary DNA microarray analysis {#cas13871-sec-0007}
------------------------------------------

The experimental procedure for the cDNA microarray analysis was based on the manufacturer\'s protocol (Agilent Technologies, Santa Clara, CA, USA). In brief, cDNA synthesis and cRNA labeling with the cyanine 3 dye were carried out using the Agilent Low Input Quick Amp Labeling Kit (Agilent Technologies). The cyanine 3‐labeled cRNA was purified, fragmented, and hybridized on a Human Gene Expression 4 × 44K v2 Microarray Chip containing 27 958 Entrez Gene RNAs, using a Gene Expression Hybridization kit (Agilent Technologies). The raw and normalized microarray data have been submitted to the GEO database at NCBI (accession no. [GSE116000](GSE116000); <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116000>). Gene set enrichment analysis was carried out according to the instructions.

2.6. Cell growth assay {#cas13871-sec-0008}
----------------------

The cell growth rate was determined by an MTT assay. Briefly, the cells (1 × 10^3^ cells/well) were seeded into a 96‐well plate and cultured for indicated times. Subsequently, 10 μL MTT solution (5 mg/mL; Sigma‐Aldrich) was added to each well, and the cells were further incubated for 4 hours. Next, the cell lysis buffer was added to the wells to dissolve the colored formazan crystals produced by MTT. The absorbance at 595 nm was measured using a SpectraMAX M5 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).

2.7. Soft agar colony formation assay {#cas13871-sec-0009}
-------------------------------------

The soft agar colony formation assay was carried out as described previously.[22](#cas13871-bib-0022){ref-type="ref"} The number of colonies was counted using Colony Counter software (Keyence, Tokyo, Japan). The data are presented as mean ± SEM (n  = 3).

2.8. Wound healing assay and migration assay {#cas13871-sec-0010}
--------------------------------------------

The cells were cultured as a monolayer in 12‐well plates. Upon reaching approximately 60%‐70% confluence, wounds were made by scratching using pipette tips. After washing with PBS, the wounds were photographed every 24 hours. Ten thousand cells suspended in 100 μL serum‐free medium were added into the upper chambers of a Transwell (8 μm for 24‐well plate; Millipore, Tokyo, Japan), and culture medium was added into the lower chambers. After 24 hours, the cells were fixed by formalin and stained by 0.1% crystal violet. The number of colonies was manually counted under a microscope.

2.9. Western blot analysis {#cas13871-sec-0011}
--------------------------

Western blot analysis was carried out as described previously.[22](#cas13871-bib-0022){ref-type="ref"} The antibodies used in this study are described in [Table S2](#cas13871-sup-0006){ref-type="supplementary-material"}. Immune complexes were detected using ImmunoStar LD (Wako) in conjunction with a LAS‐4000 image analyzer (GE Healthcare, Tokyo, Japan).

2.10. Immunohistochemistry {#cas13871-sec-0012}
--------------------------

Immunohistochemical analysis was carried out according to the procedure previously described.[23](#cas13871-bib-0023){ref-type="ref"} The human mesothelioma tissue array was purchased from US Biomax (MS‐801a; Rockville, MD, USA). The sections were reacted with a primary Ab (anti‐FGFR2 or anti‐NF2 Ab, 2 μg/mL). Normal rabbit IgG or omission of primary Abs served as negative controls. Immunoreactivity was evaluated independently by 2 investigators (S.K. and H.M.). The intensity of staining was scored as strong (3+), moderate (2+), weak (1+), or negative (0).

2.11. Statistical analysis {#cas13871-sec-0013}
--------------------------

Results are expressed as mean ± SE. Statistical significance between groups was determined using one‐way ANOVA and Dunnett\'s comparison. Statistical analyses were undertaken using SPSS 23.0 program (SPSS, Chicago, IL, USA).

3. RESULTS {#cas13871-sec-0014}
==========

3.1. Loss of *NF2* enhances cell proliferation, colony formation, and migration in MeT‐5A cells {#cas13871-sec-0015}
-----------------------------------------------------------------------------------------------

To investigate the role of NF2 in the survival and proliferation of MPM cells, we established *NF2*‐knockout cell clones (hereafter called NF2‐KO \#1 and \#2) in a human mesothelial cell line, MeT‐5A, by using a CRISPR/Cas9 system targeting exon 8 of the *NF2* gene. DNA sequencing analysis showed that the NF2‐KO cell clones possessed frameshift mutations, which harbored either 200‐bp (NF2‐KO \#1) or 22‐bp (NF2‐KO \#2) deletions in the *NF2* gene (Figure [1](#cas13871-fig-0001){ref-type="fig"}A). We also randomly selected two MeT5A/*NF2* ^*+/+*^ cell clones (hereafter called NF2‐WT \#1 and \#2), which had not been targeted by the Cas9 vector. Western blot analysis detected no protein expression of NF2 in the NF2‐KO clones, but solid NF2 expression in the parental cells and NF2‐WT clones (Figure [1](#cas13871-fig-0001){ref-type="fig"}B). Using these established clones, we first examined the cell proliferation using the MTT assay, and found that the cell growth ratio was significantly increased in the NF2‐KO clones, compared with that in the parental cells and NF2‐WT clones (Figure [2](#cas13871-fig-0002){ref-type="fig"}A). In addition, NF2‐KO clone formed more colonies in soft agar, compared with NF2‐WT clones and parent (Figure [2](#cas13871-fig-0002){ref-type="fig"}B). Furthermore, migration and wound‐healing activities were significantly higher in the NF2‐KO clone (Figure [2](#cas13871-fig-0002){ref-type="fig"}C,D). To further confirm the effect of NF2 on the tumorigenic properties of the NF2‐KO cells, we generated the cells exogenously expressing NF2 in the NF2‐KO clone (hereafter called NF2/NF2‐KO \#1 and \#2). We found that rescuing NF2 in the NF2‐KO cells significantly suppressed the cell proliferation, colony formation, migration, and wound‐healing activities induced by *NF2* mutation (Figure [2](#cas13871-fig-0002){ref-type="fig"}). These results suggest that *NF2* inactivation enhances the proliferation, clonogenicity, and migration of normal mesothelial cells. Similar to our results, the significance of *NF2* mutation in the proliferation, clonogenicity, and migration of MPM cells has been reported elsewhere.[17](#cas13871-bib-0017){ref-type="ref"}, [18](#cas13871-bib-0018){ref-type="ref"}, [24](#cas13871-bib-0024){ref-type="ref"}, [25](#cas13871-bib-0025){ref-type="ref"}

![Generation of neurofibromatosis type 2 (*NF2*) knockout (NF2‐KO) cell clones using a CRISPR/Cas9 system with the human mesothelial cell line MeT‐5A. A, A single guide RNA sequence was designed against exon 8 of the *NF2* locus. Sequences of the parental and NF2‐KO cell clones \#1 (200‐bp deletion) and \#2 (22‐bp deletion) were analyzed, and the results are shown below. The single guide RNA sequence and the protospacer adjacent motif (PAM) sequence are indicated by a black and green overline, respectively. The exon 8 sequence of *NF2* is described in blue letters. B, NF2 protein expression was determined by western blot analysis. GAPDH was used as an internal control](CAS-110-180-g001){#cas13871-fig-0001}

![Cellular phenotype of neurofibromatosis type 2 knockout (NF2‐KO) MeT‐5A cells. A, MTT analysis of the growth rate of parental MeT‐5A cells, control NF2‐WT cell clones (\#1 and \#2), NF2‐KO cell clones (\#1 and \#2), and NF2/NF2‐KO cell clones (\#1 and \#2). The relative optical density (OD) at 595 nm was calculated by dividing the OD of day 0 at each time point (days 0, 1, 3, 5, and 7) and is presented as the mean ± SEM (n = 3). B, Representative soft agar colony formation assay. Two hundred cells of each clone were seeded in a 6‐well plate. After 14 days, the cells were stained with MTT and imaged. Right bar graphs represent the number of stained colonies. Data are presented as the mean ± SEM (n = 3). C, Representative migration assay with a Boyden chamber. Cells were seeded in a Boyden chamber on a 24‐well plate (2.5 × 10^5^ cells/well). After 24 hours, the cells were stained with crystal violet and imaged. Right bar graph represents the number of stained colonies. Data are presented as the mean ± SEM (n = 3). D, Representative scratch assay. Each cell clone was seeded in a 24‐well plate (1 × 10^5^ cells/well) and incubated at 37°C. When the cell density reached \~60%‐70% confluence, the cells were gently scratched with a new 1‐mL pipette tip across the center of the well. After scratching, the cells were incubated for 48 hours and then stained with crystal violet and imaged. \*Statistically significant difference (*P *\<* *.05)](CAS-110-180-g002){#cas13871-fig-0002}

3.2. Global gene expression change induced by disruption of *NF2* {#cas13871-sec-0016}
-----------------------------------------------------------------

To identify the genes related to enhanced proliferation in the NF2‐KO clones, we undertook comprehensive cDNA microarray analyses in parental cells, NF2‐WT, and NF2‐KO clones. To compare the gene expression profiles of NF2‐KO with NF2‐WT and parental cells, normalized values of raw microarray data were calculated and clustered according to the differential gene expression. We successively detected 17 genes whose expression was upregulated more than 5‐fold ([Table S3](#cas13871-sup-0007){ref-type="supplementary-material"}) and 77 genes whose expression was downregulated less than 0.2‐fold ([Table S4](#cas13871-sup-0008){ref-type="supplementary-material"}). In addition, with the aid of Gene Set Enrichment Analysis, the genes related to positive regulation of the cell cycle were shown to be significantly activated in the NF2‐KO clones compared with the levels in the NF2‐WT clones ([Figure S1A](#cas13871-sup-0001){ref-type="supplementary-material"}). The results of Gene Set Enrichment Analysis also showed that some of the downregulated genes overlapped with the genes whose expression levels were reported to be lower in patients with biphasic‐type MPM than in those with epithelial‐type MPM ([Figure S1B](#cas13871-sup-0001){ref-type="supplementary-material"}).[26](#cas13871-bib-0026){ref-type="ref"} In addition, the clustering of the 94 genes showed a distinct gene expression pattern between NF2‐KO and NF2‐WT and parental cells (Figure [3](#cas13871-fig-0003){ref-type="fig"}A). To further confirm the effect of *NF2* on the gene expression changes in the NF2‐KO clone, we undertook RT‐PCR analyses for the 18 candidate genes related to cell survival, proliferation, or tumorigenesis. Agarose gel electrophoresis of RT‐PCR products showed decreases in the mRNA expression of *LAMA1*,*JAG1*,*NKD2*,*PBX1*,*RASSF2*,*PXDN*,*ABRACL*,*ACTA2*,*COLEC12*,*MGST2*,*PLAU*,*MAPRE2*, and *IFI27* genes, and increases in the expression of *FGFR2*,*KCND3*,*KRT4*,*MET*,*FAM155A*, and *ITM2A* in the NF2‐KO clones, compared with the levels in NF2‐WT and parental cells (Figure [3](#cas13871-fig-0003){ref-type="fig"}B). We found that the changes in mRNA expression were all abrogated in the NF2/NF2‐KO clones except the *MGST2*,*COLEC12*,*NKD2*,*ACTA2*,*IFI27*, and *FAM155A* genes (Figure [3](#cas13871-fig-0003){ref-type="fig"}B). We undertook further qRT‐PCR to precisely compare the gene expression levels among the clones. The results showed that the mRNA expression of *FGFR2*,*ITM2A*,*JPH1*,*KCND3*, and *KRT4* significantly increased, whereas that of *LAMA*,*PXDN*,*PBX1*,*RASSF2*,*MAPE2*, and *ABRACL* significantly decreased in the NF2‐KO cells (Figure [4](#cas13871-fig-0004){ref-type="fig"}). Similarly, the changes in gene expression were abrogated in the exogenous NF2/NF2‐KO clones (Figure [4](#cas13871-fig-0004){ref-type="fig"}). The results of qRT‐PCR further confirmed that rescuing NF2 had no significant effect on the mRNA expression of *MGST2*,*COLEC12*,*NKD2*,*ACTA2*,*IFI27*, or *FAM155A* genes ([Figure S2](#cas13871-sup-0002){ref-type="supplementary-material"}). These results strongly suggest that the affected gene products might function downstream of NF2 signaling.

![Gene expression analysis. Parental MeT‐5A cells and each cell clone were seeded in a 6‐well plate and incubated for 24 hours. Total RNA was extracted and cDNA microarray analysis was carried out using an Agilent Whole Human Genome cDNA Microarray Kit (4 × 44K; design ID, 026652; Agilent Technologies, Santa Clara, CA, USA). A, Heatmap of upregulated genes (17 genes; fold change, \>5.0) and downregulated genes (77 genes, fold change \<0.2) in neurofibromatosis type 2 knockout (NF2‐KO) cell clones (\#1 and \#2), compared with NF2‐WT cell clones (\#1 and \#2) and parental (P) cells. The heatmap was constructed using normalized values of each sample with TreeView (Cluster 3.0) software ([http://jtreeeview soure forge .net](http://jtreeeviewsoureforge.net)). Corresponding upregulated or downregulated genes in the heatmap are shown at the right side. B, RT‐PCR analysis of mRNA expression levels of the upregulated or downregulated genes in the MeT‐5A cell clones. Representative results of agarose gel electrophoresis of RT‐PCR products from parental MeT‐5A cells, control NF2‐WT cell clones (\#1 and \#2), NF2‐KO cell clones (\#1 and \#2), and NF2‐KO cell clones exogenously expressing NF2 (NF2/NF2‐KO \#1 and \#2) are shown](CAS-110-180-g003){#cas13871-fig-0003}

![Quantitative real‐time PCR analysis. Eleven genes, whose upregulation (A) or downregulation (B) in neurofibromatosis type 2 knockout (NF2‐KO) cell clones was detected in cDNA microarray analysis, were subjected to quantitative real‐time PCR analysis using the SYBR Green method. Relative gene expression levels are shown after normalization to *GAPDH* mRNA expression. Mean values were compared with the normal control value to calculate relative amounts of transcripts. Data are presented as mean ± SEM (n = 3). \*Statistically significant difference (*P *\<* *.05)](CAS-110-180-g004){#cas13871-fig-0004}

3.3. Effect of *NF2* knockout on FGFR2 expression and cell cycle‐related molecules {#cas13871-sec-0017}
----------------------------------------------------------------------------------

As therapy targeting the FGF--FGFR axis has emerged as a novel anticancer application in a panel of solid cancers,[27](#cas13871-bib-0027){ref-type="ref"}, [28](#cas13871-bib-0028){ref-type="ref"}, [29](#cas13871-bib-0029){ref-type="ref"} we next focused on FGFR2, whose expression was found to increase in the NF2‐KO MeT‐5A cells (Figure [5](#cas13871-fig-0005){ref-type="fig"}A). In addition, the phosphorylation levels of both ERK and JNK MAPKs, increased in the NF2‐KO clones, whereas the level of p38 MAPK remained constant (Figure [5](#cas13871-fig-0005){ref-type="fig"}A). Similarly, the phosphorylation level of c‐Jun increased in the NF2‐KO cell clones (Figure [5](#cas13871-fig-0005){ref-type="fig"}A). Furthermore, both phosphorylation levels of a cell cycle regulator, Rb, and protein expression levels of CDK2 and cyclin D1 increased in the NF2‐KO cell clones (Figure [5](#cas13871-fig-0005){ref-type="fig"}A). We also observed that, in spite of an abundant increase in the total YAP level, the YAP phosphorylation level decreased in the NF2‐KO cell clones (Figure [5](#cas13871-fig-0005){ref-type="fig"}A). To confirm the effect of NF2 on the expression of these proteins, we utilized the exogenous NF2/NF2‐KO cell clones. Rescuing of NF2 protein expression resulted in a reduction in FGFR2 expression in the NF2/NF2‐KO clones compared with that in the NF2‐KO clones (Figure [5](#cas13871-fig-0005){ref-type="fig"}B), consistent with the results of qRT‐PCR analysis. Furthermore, the other changes in protein expression and phosphorylation were all abrogated in the exogenous NF2/NF2‐KO cell clones (Figure [5](#cas13871-fig-0005){ref-type="fig"}B). Additionally, knockout of *NF2* in other normal mesothelial cell lines, HOMC‐A4, and HOMC‐D4 substantially increased the FGFR2 protein levels (Figure [5](#cas13871-fig-0005){ref-type="fig"}C). In another human mesothelioma cell line NCI‐H2052, we did not find any endogenous expression of NF2 protein. Interestingly, exogenous expression of NF2 in this cell line clearly decreased the FGFR2 protein level (Figure [5](#cas13871-fig-0005){ref-type="fig"}D). These results suggest that FGFR2 expression might be negatively regulated by NF2 signaling in the mesothelial cells.

![Protein expression analyses. A, Western blot analysis showing protein expression of neurofibromatosis type 2 (NF2), fibroblast growth factor receptor 2 (FGFR2), phosphorylation levels of MAPKs (P‐ERK1/2, P‐JNK, and P‐p38), phospho‐c‐Jun (P‐c‐Jun), phospho‐retinoblastoma (P‐Rb), cyclin‐dependent kinase 2 (CDK2), Cyclin D1, and phospho‐yes‐associated protein (P‐YAP) in the parental MeT‐5A cells, control NF2‐WT clones, and NF2‐KO clones. Cell lysates obtained were subjected to western blotting analysis to detect each protein level by using specific Abs. B, Effect of exogenous NF2 expression in NF2/NF2‐KO clones on the protein levels of FGFR2, P‐JNK, P‐c‐Jun, cyclin D1, CDK2, P‐Rb, and P‐YAP. The NF2/pcDNA3.1 vector was transfected in the NF2‐KO clones using a 4D‐Nucleofector instrument (Lonza Japan, Tokyo, Japan). C, Western blot analysis showing the protein expression of NF2 and FGFR2 in *NF2*‐knockout human mesothelial cell lines HOMC‐A4 and HOMC‐D4. D, Western blot analysis showing the protein expression of NF2 and FGFR2 due to overexpression of NF2 in the mesothelioma cell line NCI‐H2052. Cells were transfected with control pcDNA3.1 (Con‐V) and WT NF2/pcDNA3.1 vectors. After transfection, the cells were incubated for 48 hours, washed with PBS and lysed in loading buffer. The cell lysates obtained were subjected to western blotting analysis. GAPDH was used as an internal control](CAS-110-180-g005){#cas13871-fig-0005}

3.4. Knockout of *FGFR2* gene retards cell proliferation in the absence of *NF2* gene {#cas13871-sec-0018}
-------------------------------------------------------------------------------------

To clarify the role of FGFR2 in the proliferation of NF2‐KO cells, we generated *NF2* and *FGFR2* double knockout cell clones (hereafter called NF2/FGFR2‐DKO \#1 and \#2) as well as *FGFR2* knockout cell clone (hereafter called FGFR2‐KO). The MTT assay showed that the cell growth ratio significantly decreased in the NF2/FGFR2‐DKO clones compared with that in the NF2‐KO clones (Figure [6](#cas13871-fig-0006){ref-type="fig"}A). In contrast, the growth ratio did not significantly alter between FGFR2‐KO and parental cells (Figure [6](#cas13871-fig-0006){ref-type="fig"}B). In addition, disruption of *FGFR2* in NF2‐KO cells suppressed the *NF2* knockout‐induced migration and wound healing activities of NF2/FGFR2‐DKO cells (Figures [6](#cas13871-fig-0006){ref-type="fig"}C,D). Furthermore, western blot analysis showed that the phosphorylation levels of JNK and c‐Jun were downregulated in the NF2/FGFR2‐DKO clones (Figure [6](#cas13871-fig-0006){ref-type="fig"}E). We also found that the protein level of CDK2 and the phosphorylation level of Rb decreased in the NF2/FGFR2‐DKO clones (Figure [6](#cas13871-fig-0006){ref-type="fig"}E). These results indicate the possibility that FGFR2 could play important role in the proliferation of mesothelioma cells with *NF2* mutation.

![Cellular phenotype of neurofibromatosis type 2/fibroblast growth factor receptor 2 (*NF2/FGFR2*) double knockout (DKO) in MeT‐5A cells. A, MTT analysis of the growth rate of NF2‐KO cell clones (\#1 and \#2) and NF2/FGFR2‐DKO cell clones (\#1 and \#2) in MeT‐5A cells. The optical density (OD; 595 nm) at each time point (days 0, 3, 5, and 7) is presented as the mean ± SEM (n = 6). Data of growth ratio are expressed relative to the optical densities detected at day 0, which are arbitrarily defined as 1. B, Representative MTT assay for the growth ratio of parental and FGFR2‐KO cell clone. C,D, Representative images of Boyden chamber migration assay (C) and scratch assay (D). E, Western blotting showing the protein expression of FGFR2, P‐JNK,JNK, P‐c‐Jun, cyclin‐dependent kinase 2 (CDK2), phospho‐retinoblastoma (P‐Rb), and GAPDH in NF2‐KO cells and NF2/FGFR2‐DKO cells. \*Statistically significant difference (*P *\<* *.05)](CAS-110-180-g006){#cas13871-fig-0006}

3.5. Relationship between YAP activity and FGFR2 expression {#cas13871-sec-0019}
-----------------------------------------------------------

It has been reported that *NF2* mutation activates a downstream YAP oncogenic signaling pathway, which leads to cell cycle progression and induces carcinogenesis.[30](#cas13871-bib-0030){ref-type="ref"} Consistent with a previous study reporting the decreased level of YAP phosphorylation in *NF2*‐deficient cells,[31](#cas13871-bib-0031){ref-type="ref"} we also observed the decreased phosphorylation level of YAP in our NF2‐KO clones (Figure [5](#cas13871-fig-0005){ref-type="fig"}A). To clarify the involvement of YAP in FGFR2 expression, we examined the effects of exogenous YAP expression and/or knockdown of *YAP* on FGFR2 expression. The FGFR2 protein expression was not upregulated by exogenous expression of either constitutively active YAP^S127/381A^ mutant or WT YAP, regardless of *NF2* loss (Figure [7](#cas13871-fig-0007){ref-type="fig"}A). Consequently, *NF2* knockout‐induced FGFR2 expression did not significantly change under *YAP* knockdown with YAP sh2 vector, whereas it decreased under *YAP* knockdown with YAP sh1 vector (Figures [7](#cas13871-fig-0007){ref-type="fig"}B,C). We also found that the phosphorylation level of c‐Jun increased after exogenous YAP expression, whereas it decreased following *YAP* knockdown ([Figure S3](#cas13871-sup-0003){ref-type="supplementary-material"}).

![Effect of yes‐associated protein (YAP) expression and *YAP* knockdown on fibroblast growth factor receptor 2 (FGFR2) expression. A, Effect of exogenous expression of YAP on FGFR2 expression. Neurofibromatosis type 2 (NF2)‐WT and knockout (NF2‐KO) cells were transfected with control pcDNA3.1, WT YAP/pcDNA3.1, or active mutant YAP^S^ ^127/381A^/pcDNA3.1 by using nucleofection. After 48 hours of incubation, the cell lysates were prepared and subjected to western blot analysis. Each protein was detected using specific Abs, and representative images are shown. B,C, Effect of *YAP* knockdown on FGFR2 expression. NF2‐WT and NF2‐KO cells were transfected with either YAP sh1 (B) or YAP sh2 (C) and control shRNA vectors. After 48 hours of incubation, the cell lysates were prepared and subjected to western blot analysis, as described above](CAS-110-180-g007){#cas13871-fig-0007}

3.6. Immunohistochemistry for FGFR2 expression in patients with MPM {#cas13871-sec-0020}
-------------------------------------------------------------------

Finally, we undertook immunohistochemical analyses to examine the protein expression level of FGFR2 in 23 malignant mesotheliomas and 10 normal mesothelium tissue samples (Table [1](#cas13871-tbl-0001){ref-type="table"}, Figure [8](#cas13871-fig-0008){ref-type="fig"}A). Microscopy analysis showed 3 strong (3+), 8 moderate (2+), and 2 weak (1+) FGFR2‐positive signals in MPM tissues, whereas only 1 weak (1+) signal of FGFR2 expression was found in normal mesothelium tissues (Table [1](#cas13871-tbl-0001){ref-type="table"}, Figure [8](#cas13871-fig-0008){ref-type="fig"}B). Interestingly, the rate of positivity for FGFR2 signals in the NF2‐negative MPM tissues (11 of 12 tissues, 91.7%) was significantly higher than that in the NF2‐positive MPM tissues (2 of 11 tissues, 18.2%; Figure [8](#cas13871-fig-0008){ref-type="fig"}). Our analysis using data in the public domain (GSE2549 and GSE29354, deposited in GEO datasets) clarified that *FGFR2* mRNA expression in patients with MPM was higher than that in normal pleura ([Figure S4A](#cas13871-sup-0004){ref-type="supplementary-material"}). Notably, overall survival in the MPM patients with high FGFR2 expression was shorter than in those with low FGFR2 expression in both datasets ([Figure S4B](#cas13871-sup-0004){ref-type="supplementary-material"}). Collectively, these results strongly indicate the possibility that the loss of *NF2* results in the increased expression of FGFR2, which might be closely associated with poor prognosis in MPM.

###### 

Summary of immunohistochemistry in this study

  Case   Sex   Age, years   Organ                 Pathology                                                 Stage   Type        NF2 intensity   FGFR2 intensity
  ------ ----- ------------ --------------------- --------------------------------------------------------- ------- ----------- --------------- -----------------
  1      F     70           Abdominal cavity      Epithelial malignant mesothelioma                         IV      Malignant   2+              2+
  2      M     60           Abdominal cavity      Malignant mesothelioma of abdominal membrane              II      Malignant   3+              0
  3      M     5            Abdominal cavity      Malignant mesothelioma                                    N/A     Malignant   0               2+
  4      M     60           Abdominal cavity      Malignant mesothelioma of abdominal membrane              N/A     Malignant   2+              0
  5      F     47           Abdominal cavity      Malignant mesothelioma (sparse)                           I       Malignant   0               2+
  6      M     33           Abdominal cavity      Epithelial malignant mesothelioma of abdominal membrane   IV      Malignant   2+              0
  7      F     38           Abdominal cavity      Malignant mesothelioma                                    IV      Malignant   0               2+
  8      M     63           Retroperitoneum       Malignant mesothelioma                                    N/A     Malignant   3+              2+
  9      M     48           Heart                 Epithelial malignant mesothelioma of abdominal membrane   II      Malignant   2+              0
  10     M     43           Heart                 Epithelial malignant mesothelioma                         IIB     Malignant   0               2+
  11     F     23           Lung                  Malignant mesothelioma                                    II      Malignant   0               1+
  12     F     18           Lung                  Malignant mesothelioma                                    I       Malignant   0               1+
  13     F     56           Mediastinum           Malignant mesothelioma of pleura                          II      Malignant   2+              0
  14     F     58           Pleura                Malignant mesothelioma (sparse)                           I       Malignant   2+              0
  15     F     22           Pleura                Malignant mesothelioma of thoracic cavity                 I       Malignant   0               2+
  16     F     70           Pleura                Malignant mesothelioma of right pleura                    II      Malignant   0               3+
  17     M     47           Pleura                Malignant mesothelioma of left pleura                     II      Malignant   0               0
  18     M     49           Pleura                Malignant mesothelioma                                    I       Malignant   0               3+
  19     F     64           Pleura                Epithelial malignant mesothelioma of chest wall           II      Malignant   0               3+
  20     M     49           Pleura                Malignant mesothelioma                                    I       Malignant   0               2+
  21     M     83           Pleura                Malignant mesothelioma                                    III     Malignant   2+              0
  22     M     50           Cardiac pericardium   Malignant mesothelioma                                    I       Malignant   2+              0
  23     M     43           Cardiac pericardium   Malignant mesothelioma                                    I       Malignant   3+              0
  24     M     34           Pleura                Normal mesothelium tissue (lung tissue)                   N/A     Normal      2+              0
  25     F     15           Cardiac pericardium   Normal mesothelium tissue                                 N/A     Normal      3+              0
  26     M     28           Cardiac pericardium   Normal mesothelium tissue (sparse)                        N/A     Normal      2+              0
  27     F     27           Cardiac pericardium   Normal mesothelium tissue                                 N/A     Normal      2+              0
  28     M     43           Cardiac pericardium   Normal mesothelium tissue                                 N/A     Normal      3+              0
  29     M     19           Cardiac pericardium   Normal mesothelium tissue                                 N/A     Normal      2+              0
  30     F     21           Lung                  Normal mesothelium tissue                                 N/A     Normal      3+              0
  31     F     21           Lung                  Normal mesothelium tissue (lung tissue)                   N/A     Normal      3+              1+
  32     M     47           Lung                  Normal mesothelium tissue                                 N/A     Normal      2+              0
  33     M     19           Lung                  Normal mesothelium tissue (sparse)                        N/A     Normal      3+              0

Intensity of the positive signals for neurofibromatosis type 2 (NF2) and fibroblast growth factor receptor 2 (FGFR2) was evaluated by 2 investigators.F, female; M, male; N/A, not analyzed.
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![Immunohistochemistry (IHC) for neurofibromatosis type 2 (NF2) and fibroblast growth factor receptor 2 (FGFR2) expression. A, Representative results of IHC for NF2 (left panels) and FGFR2 (right panels) expression in NF2‐negative malignant pleural mesothelioma (MPM) tissue (upper panels, case 16), NF2‐positive MPM tissue (middle panels, case 2), and normal mesothelium tissue (lower panels, case 31). B, Summary of IHC results in MPM tissues. The immunoreactivities were independently evaluated by 2 investigators. The intensity of staining was scored as strong (3+), moderate (2+), weak (1+), or negative (0). The bar graph represents the percentage of total number of cases with FGFR2 expression (strong, moderate and weak) in the MPM tissues with NF2 negative or NF2 positive (strong, moderate, and weak) cases](CAS-110-180-g008){#cas13871-fig-0008}

4. DISCUSSION {#cas13871-sec-0021}
=============

Recent molecular biological studies have revealed frequent genetic alterations of 3 key tumor suppressor genes, *NF2*,*CDKN2A*, and *BAP1*, in MPM. In this study, we generated *NF2* knockout isogenic cell clones using a human immortalized normal mesothelial cell line, MeT‐5A, and showed that the loss of *NF2* enhances cell proliferation with global gene expression changes. Our study strongly suggests that FGFR2 expression might be the downstream event of NF2 in MPM tissues and be correlated with overall survival of MPM patients. Furthermore, we showed that the loss of *FGFR2* attenuates the proliferation of NF2‐KO MeT‐5A cells.

The CRISPR/Cas9 system makes it readily possible to disrupt target genes by inducing insertion/deletion and to introduce specific gene polymorphism/mutation by inducing homologous recombination. Our cellular model presented here is the first to reveal the gene expression profile under complete disruption of *NF2* in human normal mesothelial cells. Using the NF2‐KO cell clones, we found that loss of the *NF2* gene in MeT‐5A cells enhances cell proliferation, clonogenicity, and cell migration, as previously described.[19](#cas13871-bib-0019){ref-type="ref"} Using comprehensive gene expression analysis, we found that gene expression in the NF2‐KO cell clones was distinct from that in the NF2‐WT cells. Quantitative RT‐PCR analysis revealed that the mRNA expression of *FGFR2*,*ITAM2A*,*JPH1*,*KCND3*,*KRT4*,*LAMA1*,*PXDN*,*PBX1*, and *RASSF2* was closely associated with *NF2* expression. Our results of gene expression profiling showed that the loss of *NF2* significantly enhanced the expression of genes related to positive regulation of the cell cycle phase and suppressed the expression of certain other genes, some of which were reported to be downregulated in malignant mesothelioma.[26](#cas13871-bib-0026){ref-type="ref"}

Fibroblast growth factor receptor family protein has been shown to be amplified and overexpressed in several cancer types.[32](#cas13871-bib-0032){ref-type="ref"}, [33](#cas13871-bib-0033){ref-type="ref"}, [34](#cas13871-bib-0034){ref-type="ref"}, [35](#cas13871-bib-0035){ref-type="ref"}, [36](#cas13871-bib-0036){ref-type="ref"}, [37](#cas13871-bib-0037){ref-type="ref"} Expression of FGFR2 protein was observed in several types of cancer including breast and gastric cancer.[38](#cas13871-bib-0038){ref-type="ref"}, [39](#cas13871-bib-0039){ref-type="ref"} Fibroblast growth factor receptor 1 has been reported to be a growth driver in MPM.[28](#cas13871-bib-0028){ref-type="ref"}, [40](#cas13871-bib-0040){ref-type="ref"} Recent data reported by The Cancer Genome Atlas lung squamous cell carcinoma project showed that the FGFR tyrosine kinases are some of the most frequently altered kinase families in lung squamous cell carcinoma.[41](#cas13871-bib-0041){ref-type="ref"} Interestingly, Quispel‐Janssen et al[29](#cas13871-bib-0029){ref-type="ref"} recently reported that a subgroup of immortalized and primary MPM lines appeared to be highly sensitive to FGFR inhibition. They also showed an association between *BAP1* loss and increased expression of the receptors FGFR1/3 and ligands FGF9/18.[29](#cas13871-bib-0029){ref-type="ref"} Taken together with these reports, our study indicates the possibility that the FGF‐FGFR axis could play an important role in the molecular pathogenesis of MPM.

Our immunohistochemical study showed that FGFR2 was commonly expressed (in 11 of 12) in NF2‐negative MPM tissues, whereas it was rarely expressed (in 2 of 11) in NF2‐positive MPM tissues. Additionally, *NF2* loss resulted in the increased expression of *FGFR2*, and subsequent rescue of NF2 expression decreased its expression in MeT‐5A cells. In other normal mesothelial cell lines HOMC‐A4 and HOMC‐D4, we also found that knockout of *NF2* causes a substantial increase in FGFR2 protein level. In contrast, exogenous expression of NF2 in an NF2‐deficient human mesothelioma cell line NCI‐H2052 led to a decrease in FGFR2 protein level. These results indicate the possibility that FGFR2 expression is intimately regulated by NF2 expression. Furthermore, knockout of *FGFR2* in NF2‐KO cells led to retardation of cell growth, accompanied by decreases in the phosphorylation of JNK, c‐Jun, and Rb, as well as the expression of CDK2. These results strongly suggest that FGFR2 could play a pivotal role in the proliferation of NF2‐KO cells.

A transcription factor in the downstream of NF2 signaling, YAP/TAZ, was reported to be critical for the carcinogenesis of mesothelial cells with *NF2* loss.[30](#cas13871-bib-0030){ref-type="ref"}, [31](#cas13871-bib-0031){ref-type="ref"} Our previous study reported c‐Jun amplification in a panel of MPM tumors.[42](#cas13871-bib-0042){ref-type="ref"} In this study, we observed that overexpression of constitutively active YAP mutant does not alter the FGFR2 protein level in the NF2‐KO clone, whereas it increases the phosphorylation levels of c‐Jun and cyclin D1. In addition, we found that FGFR2 protein expression does not significantly change under *YAP* knockdown with YAP sh2 vector, whereas it decreases under *YAP* knockdown with YAP sh1 vector in the NF2‐KO clone. Our data could not exclude the possibility that YAP activity is related to *NF2* knockout‐induced FGFR2 expression. Further studies are necessary to clarify the molecular mechanism by which loss of *NF2* increases *FGFR2* expression in mesothelial cells.

In conclusion, this study is the first to show the global gene expression changes following *NF2* loss in a human mesothelial cell line, MeT‐5A. The CRISPR/Cas9‐mediated loss of *NF2* enhanced the proliferation of cells and the expression of *FGFR2*, the subsequent disruption of which significantly suppressed the phosphorylation of cell cycle‐related molecules as well as enhanced the proliferation of the cells. Although the molecular mechanism underlying *NF2* loss‐mediated upregulation of *FGFR2* remains unclear, it was found that FGFR2 expression was inversely correlated with NF2 expression in MPM tissues and was associated with the survival of MPM patients. Our study strongly suggests that FGFR2 signaling might play a pivotal role in the proliferation of MPM cells. Further studies are warranted to understand the role of FGFR2 in the molecular pathogenesis in *NF2*‐disrupted MPM cells. Our findings could help to clarify the importance of the FGFR signaling pathway in MPM and to develop specific molecular‐targeted drugs for the treatment of patients with MPM.
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